Affymax completes enrollment for Phase III anemia trial (Pharmaceutical Business Review) PDF Print

Affymax, a biopharmaceutical company, has completed enrollment in Emerald 1, one of its Phase III clinical trials of its lead investigational therapy, Hematide, which is being evaluated for the treatment of anemia in chronic renal failure patients.

read more

 
Share |
Copyright © 2017 Global Dialysis. All Rights Reserved.